{"protocolSection":{"identificationModule":{"nctId":"NCT06551181","orgStudyIdInfo":{"id":"219815"},"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older","officialTitle":"A Phase 3, Randomized, Controlled, Partially Blind, Immuno-bridging Study to Evaluate Immunogenicity, Reactogenicity, Safety and the Occurrence of RSV Associated Respiratory Tract Illness After Administration of a Single Dose of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Older"},"statusModule":{"statusVerifiedDate":"2026-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-04-24","type":"ACTUAL"},"completionDateStruct":{"date":"2025-09-15","type":"ACTUAL"},"studyFirstSubmitDate":"2024-08-09","studyFirstSubmitQcDate":"2024-08-09","studyFirstPostDateStruct":{"date":"2024-08-13","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-04-24","resultsFirstSubmitQcDate":"2026-04-24","resultsFirstPostDateStruct":{"date":"2026-05-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-11-05","lastUpdatePostDateStruct":{"date":"2026-11-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the current study is to evaluate the immune response of the RSVPreF3 OA investigational vaccine in older adults (OA) at least (\\>=) 60 years of age (YOA) in China compared to OA in the same age range to be enrolled from overseas countries that participated in the RSV OA=ADJ-006 (NCT04886596) study, since the vaccine efficacy against lower respiratory tract disease (LRTD) has been demonstrated following a single dose of the RSVPreF3 OA investigational vaccine in the global efficacy study RSV OA=ADJ-006. In addition, the safety (in all participants) , reactogenicity and occurrence of RSV-associated acute respiratory illness (ARI) (in study participants in China only) after administration of the vaccine are also assessed in the current study. No ARI surveillance will be conducted for the overseas participants."},"conditionsModule":{"conditions":["Respiratory Syncytial Virus Infections"],"keywords":["Respiratory syncytial virus (RSV)","Older adults","Acute respiratory illness (ARI)","Lower respiratory tract disease (LRTD)","Immune response","Efficacy study","Safety study"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Data from study participants in China is collected in an observer-blind manner. The study is open labelled for overseas participants.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":2620,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"RSV OA vaccine Group (Overseas)","type":"EXPERIMENTAL","description":"Overseas older adults (OA) participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6).","interventionNames":["Biological: RSVPreF3 OA investigational vaccine"]},{"label":"RSV OA vaccine Group (China)","type":"EXPERIMENTAL","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later).","interventionNames":["Biological: RSVPreF3 OA investigational vaccine"]},{"label":"Placebo Group (China)","type":"EXPERIMENTAL","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later).","interventionNames":["Drug: Placebo (Saline solution)"]}],"interventions":[{"type":"BIOLOGICAL","name":"RSVPreF3 OA investigational vaccine","description":"One dose of the RSVPreF3 OA investigational vaccine is administered intramuscularly at Day 1.","armGroupLabels":["RSV OA vaccine Group (China)","RSV OA vaccine Group (Overseas)"]},{"type":"DRUG","name":"Placebo (Saline solution)","description":"One dose of placebo is administered intramuscularly at Day 1.","armGroupLabels":["Placebo Group (China)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA Vaccination","description":"RSV-A neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.","timeFrame":"At Day 31"},{"measure":"Percentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination","description":"Seroresponse was defined as at least a 4 fold (≥4) increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration).","timeFrame":"At Day 31 compared to baseline (Day 1)"},{"measure":"RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination","description":"RSV-B neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.","timeFrame":"At Day 31"},{"measure":"Percentage of Participants With Seroresponse for RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination","timeFrame":"At Day 31 compared to baseline (Day 1)"}],"secondaryOutcomes":[{"measure":"RSV-A Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination","description":"Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.","timeFrame":"At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)"},{"measure":"RSV-B Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination","description":"Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.","timeFrame":"At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)"},{"measure":"Percentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month and 6 Months Post RSVPreF3 OA Vaccination","timeFrame":"At Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination) compared to baseline (Day 1)"},{"measure":"RSV-A and RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group","description":"This outcome measure compares the adjusted GMTs for RSV-A and RSV-B for the RSV OA vaccine Group (China) to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \\[RSV OA Overseas (RSV OA=ADJ-006 study) group\\]. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.","timeFrame":"At Day 31"},{"measure":"Percentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group","description":"This outcome measure compares the seroresponse for RSV-A and RSV-B neutralizing titers in the RSV OA vaccine Group (China) group to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \\[RSV OA Overseas (RSV OA=ADJ-006 study) group\\].","timeFrame":"At Day 31 compared to baseline (Day 1)"},{"measure":"Number of Participants With Any and Real Time Polymerase Chain Reaction (RT-PCR) Confirmed RSV-A/B Associated Acute Respiratory Illness (ARI) and Lower Respiratory Tract Disease (LRTD) Cases","description":"ARI and LRTD were reported based on the case definition. Case definition for ARI: presence of at least 2 respiratory symptoms/signs for at least 24 hours or at least 1 respiratory symptom/sign and 1 systemic symptom/sign for at least 24 hours. Case definition for LRTD: presence of at least 2 lower respiratory symptoms/signs for at least 24 hours including at least 1 lower respiratory sign or at least 3 lower respiratory symptoms for at least 24 hours.","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])"},{"measure":"Duration of Episodes for RSV-confirmed ARI and LRTD Cases","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])"},{"measure":"Number of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed ARI Cases","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])"},{"measure":"Number of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed LRTD Cases","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])"},{"measure":"Number of Participants With RSV-confirmed ARI and LRTD Episodes by Severity","description":"The severity was measured as mild, moderate or severe. Mild= An ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate=An ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe=An ARI/LRTD episode which prevents normal, everyday activities. Such an event would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])"},{"measure":"Number of Participants With RSV-confirmed ARI and LRTD Episodes by Frailty Status","description":"The frailty status was evaluated as frail, pre-frail, and fit. Frail=Participants with a walking speed \\<0.4 meters per second (m/s) or who were not able to perform the test. Pre-frail=Participants with a walking speed between 0.4-0.99 m/s. Fit=Participants with a walking speed ≥1 m/s.","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])"},{"measure":"Number of Participants Reporting Any Solicited Administration Site Adverse Events","description":"Assessed solicited administration site adverse events were pain, redness (erythema) and swelling at administration site. Any = occurrence of the symptom regardless of intensity grade.","timeFrame":"Day 1 (baseline) to Day 7"},{"measure":"Number of Participants Reporting Any Solicited Systemic Adverse Events","description":"Assessed solicited systemic adverse events were fever (pyrexia), headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever was defined as body temperature greater or equal to (≥) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade.","timeFrame":"Day 1 (baseline) to Day 7"},{"measure":"Number of Participants Reporting Any Unsolicited Adverse Events (AEs)","description":"An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade.","timeFrame":"Day 1 (baseline) to Day 30"},{"measure":"Number of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs","description":"An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of the intensity grade or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.","timeFrame":"Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)"},{"measure":"Number of Participants Reporting Any Potential Immune-mediated Disease (pIMDs) and Related pIMDs","description":"pIMDs are a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of the intensity grade or relation to study vaccination. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.","timeFrame":"Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult male or female of ≥60 YOA at the time of study intervention administration, who live in the community dwelling (CD participants).\n* Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, attend regular phone calls/study site visits, perform self-swabbing (study participants in China only), ability to access and utilize a phone or other electronic communications).\n* Participants who are medically stable in the opinion of the investigator at the time of vaccination. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.\n* Written or witnessed informed consent obtained from the participant (participant must be able to understand the informed consent) prior to performance of any study specific procedure.\n\nExclusion Criteria:\n\nMedical Conditions:\n\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).\n* Any clinical conditions for which serum samples would be prohibited for transfer to local central lab for testing. These clinical conditions include hepatitis B, hepatitis C, HIV and Syphilis based on medical history and physical examination (all participants) and laboratory screening tests (overseas participants).\n* Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., current malignancy, human immunodeficiency virus) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat autoimmune disorders), based on medical history and physical examination (no laboratory testing required).\n* Any history of dementia or any medical condition that moderately or severely impairs cognition.\n* Recurrent history or uncontrolled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol (e.g. completion of the diary cards, attend regular phone calls/study site visits, perform self-swabbing (study participants in China only).\n* Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 1 year).\n* Serious or unstable chronic illness.\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.\n\nPrior/Concomitant Therapy:\n\n* Previous vaccination with RSV vaccine.\n* Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study intervention(s) during the period beginning 30 days before the dose of study intervention(s), or their planned use during the study period.\n* Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after study intervention administration, with the exception of COVID-19 and inactivated/subunit influenza vaccines which can be administered up to 14 days before or from 14 days after each study intervention.\n* Administration of long-acting immune-modifying drugs or planned administration at any time during the study period (e.g., infliximab).\n* Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention administration or planned administration during the study period.\n* Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the study intervention administration or planned administration during the study period. For corticosteroids, this will mean prednisone \\>=20 mg/day, or equivalent. Inhaled and topical steroids are allowed.\n\nPrior/Concurrent Clinical Study Experience:\n\n• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device).\n\nOther Exclusion Criteria:\n\n* History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.\n* Bedridden participants.\n* Planned move during the study conduct that prohibits participation until study end.\n* Participation of any study personnel or their immediate dependents, family, or household members.","healthyVolunteers":true,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"GSK Investigational Site","city":"Shanghai","state":"Putuo","zip":"200065","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"GSK Investigational Site","city":"Shanghai","state":"Putuo","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"GSK Investigational Site","city":"Shanghai","state":"Shanghai Municipality","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"GSK Investigational Site","city":"Shanghai","zip":"200136","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"GSK Investigational Site","city":"Shanghai","zip":"201620","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"GSK Investigational Site","city":"Shanghai","zip":"201901","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"GSK Investigational Site","city":"Shanghai","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"GSK Investigational Site","city":"Espoo","zip":"02230","country":"Finland","geoPoint":{"lat":60.2052,"lon":24.6522}},{"facility":"GSK Investigational Site","city":"Helsinki","zip":"00290","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"GSK Investigational Site","city":"Kokkola","zip":"67100","country":"Finland","geoPoint":{"lat":63.83847,"lon":23.13066}},{"facility":"GSK Investigational Site","city":"Oulu","zip":"90220","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"GSK Investigational Site","city":"Seinäjoki","zip":"60100","country":"Finland","geoPoint":{"lat":62.79446,"lon":22.82822}},{"facility":"GSK Investigational Site","city":"Tampere","zip":"33100","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"GSK Investigational Site","city":"Turku","zip":"20520","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"GSK Investigational Site","city":"Tokyo","zip":"160-0017","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"GSK Investigational Site","city":"Elblag","zip":"82-300","country":"Poland","geoPoint":{"lat":54.1522,"lon":19.40884}},{"facility":"GSK Investigational Site","city":"Katowice","zip":"40-282","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"GSK Investigational Site","city":"Katowice","zip":"40-600","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"GSK Investigational Site","city":"Krakow","zip":"31-501","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"GSK Investigational Site","city":"Lodz","zip":"91-363","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"GSK Investigational Site","city":"Lublin","zip":"20-362","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"GSK Investigational Site","city":"Sochaczew","zip":"96-500","country":"Poland","geoPoint":{"lat":52.22944,"lon":20.23838}},{"facility":"GSK Investigational Site","city":"Warsaw","zip":"00-215","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"GSK Investigational Site","city":"Wroclaw","zip":"50-088","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"GSK Investigational Site","city":"Guri-si","zip":"471-701","country":"South Korea","geoPoint":{"lat":37.5986,"lon":127.1394}},{"facility":"GSK Investigational Site","city":"Incheon","zip":"400-711","country":"South Korea","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"GSK Investigational Site","city":"Seoul","zip":"152-703","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"GSK Investigational Site","city":"Ávila","zip":"05071","country":"Spain","geoPoint":{"lat":40.65724,"lon":-4.69951}},{"facility":"GSK Investigational Site","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"GSK Investigational Site","city":"Burgos","zip":"09006","country":"Spain","geoPoint":{"lat":42.34106,"lon":-3.70184}},{"facility":"GSK Investigational Site","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"GSK Investigational Site","city":"Salamanca","zip":"37007","country":"Spain","geoPoint":{"lat":40.96882,"lon":-5.66388}},{"facility":"GSK Investigational Site","city":"Valladolid","zip":"47003","country":"Spain","geoPoint":{"lat":41.65541,"lon":-4.72353}},{"facility":"GSK Investigational Site","city":"Witney","state":"Oxfordshire","zip":"OX29 4QB","country":"United Kingdom","geoPoint":{"lat":51.7836,"lon":-1.4854}},{"facility":"GSK Investigational Site","city":"Belfast","zip":"BT7 2EB","country":"United Kingdom","geoPoint":{"lat":54.59682,"lon":-5.92541}},{"facility":"GSK Investigational Site","city":"Blackpool","zip":"FY3 7EN","country":"United Kingdom","geoPoint":{"lat":53.81667,"lon":-3.05}},{"facility":"GSK Investigational Site","city":"Bristol","zip":"BS37 4AX","country":"United Kingdom","geoPoint":{"lat":51.45523,"lon":-2.59665}},{"facility":"GSK Investigational Site","city":"Cambridgeshire","zip":"CB7 5JD","country":"United Kingdom"},{"facility":"GSK Investigational Site","city":"Hounslow","zip":"TW3 3EL","country":"United Kingdom","geoPoint":{"lat":51.46839,"lon":-0.36092}},{"facility":"GSK Investigational Site","city":"Witney","zip":"OX28 6JS","country":"United Kingdom","geoPoint":{"lat":51.7836,"lon":-1.4854}}]},"referencesModule":{"references":[{"pmid":"42756146","type":"BACKGROUND","citation":"Guo X, Ning G, Bi D, Damaso S, Dodet M, Huang F, Zhang X, Genco F, Lu H, Zhao J, Jiang L, Wu X, Li X, Yang L, Dezutter N, Sun X, Hu J. Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults >/=60 years of age in China: results from a phase 3 immunobridging trial. Front Immunol. 2026 Sep 3;17:1894773. doi: 10.3389/fimmu.2026.1894773. eCollection 2026."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"timeFrame":"Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.","accessCriteria":"Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.","url":"https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas older adults (OA) participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."},{"id":"FG001","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"FG002","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"820"},{"groupId":"FG001","numSubjects":"1199"},{"groupId":"FG002","numSubjects":"601"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"812"},{"groupId":"FG001","numSubjects":"1176"},{"groupId":"FG002","numSubjects":"589"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"12"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"10"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas older adults (OA) participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."},{"id":"BG001","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"BG002","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"820"},{"groupId":"BG001","value":"1199"},{"groupId":"BG002","value":"601"},{"groupId":"BG003","value":"2620"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"YEARS","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70.5","spread":"6.8"},{"groupId":"BG001","value":"69.8","spread":"6.6"},{"groupId":"BG002","value":"69.9","spread":"6.7"},{"groupId":"BG003","value":"70.1","spread":"6.7"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"439"},{"groupId":"BG001","value":"618"},{"groupId":"BG002","value":"304"},{"groupId":"BG003","value":"1361"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"381"},{"groupId":"BG001","value":"581"},{"groupId":"BG002","value":"297"},{"groupId":"BG003","value":"1259"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"1199"},{"groupId":"BG002","value":"601"},{"groupId":"BG003","value":"1906"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"707"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"707"}]}]},{"title":"American Indian or Alaskan Native","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA Vaccination","description":"RSV-A neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.","populationDescription":"Analysis performed on Per Protocol Set(PPS)-all eligible participants who received study intervention,had immunogenicity results pre\\&post dose,complied with blood draw intervals,without intercurrent conditions that may interfere with immunogenicity \\& without prohibited concomitant medication.As pre-specified in Protocol,analysis was performed only on RSV OA vaccine (China) \\& RSV OA vaccine (Oversea) groups.Participants with adjusted RSV-A GMTs data available at specified timepoint were reported.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At Day 31","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"757"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5676.7","lowerLimit":"5419.3","upperLimit":"5946.2"},{"groupId":"OG001","value":"6329.5","lowerLimit":"5973.7","upperLimit":"6706.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the non-inferiority (NI) of humoral immune response in Chinese OA enrolled in the RSV OA group (China) compared to OA enrolled in the RSV OA group (Overseas), for the RSV-A strain after the RSVPreF3 OA investigational vaccine administration.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"NI was to be demonstrated if the upper limit of the 2-sided 95% confidence interval (CI) of the group GMT ratio between RSV OA vaccine Group (Overseas) over RSV OA vaccine Group (China) at 1 month post RSVPreF3 OA vaccine administration was less than or equal to (≤) 1.5.","statisticalMethod":"ANCOVA","statisticalComment":"The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.","paramType":"Group GMT Ratio","paramValue":"1.11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.04","ciUpperLimit":"1.20","estimateComment":"Comparison is done using the group ratio of adjusted GMT (RSV-OA (Overseas)/RSV-OA (China)) (ANCOVA model applied to the log10- transformed titers)."}]},{"type":"PRIMARY","title":"Percentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination","description":"Seroresponse was defined as at least a 4 fold (≥4) increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration).","populationDescription":"Analysis was performed on the PPS. As pre-specified in the Protocol, the analysis was performed only on the RSV OA vaccine Group (China) and RSV OA vaccine Group (Overseas). Participants with data available for seroresponse for RSV-A at the specified timepoint were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 31 compared to baseline (Day 1)","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"757"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","lowerLimit":"74.8","upperLimit":"79.6"},{"groupId":"OG001","value":"76.9","lowerLimit":"73.7","upperLimit":"79.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the NI of humoral immune response in Chinese OA enrolled in the RSV OA group (China) compared to OA enrolled in the RSV OA group (Overseas), for the RSV-A strain after the RSVPreF3 OA investigational vaccine administration.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"NI was to be demonstrated if the upper limit of the 2-sided 95% CI of the group Seroresponse Rate (SRR) difference between RSV OA vaccine Group (Overseas) over RSV OA vaccine Group (China) at 1 month post RSVPreF3 OA vaccine administration was ≤10%.","paramType":"Group SRR difference","paramValue":"-0.39","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.29","ciUpperLimit":"3.40","estimateComment":"Comparison is done using the difference of SRR (RSV-OA (Overseas) -RSV-OA (China))."}]},{"type":"PRIMARY","title":"RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination","description":"RSV-B neutralizing titers were determined by neutralization assay and the results were expressed as GMTs. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.","populationDescription":"Analysis was performed on the PPS. As pre-specified in the Protocol, the analysis was performed only on the RSV OA vaccine Group (China) and RSV OA vaccine Group (Overseas). Participants with adjusted RSV-B GMTs data available at the specified timepoint were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At Day 31","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"757"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8072.8","lowerLimit":"7710.8","upperLimit":"8451.9"},{"groupId":"OG001","value":"8286.8","lowerLimit":"7826.4","upperLimit":"8774.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the NI of humoral immune response in Chinese OA enrolled in the RSV OA group (China) compared to OA enrolled in the RSV OA group (Overseas), for the RSV-B strain after the RSVPreF3 OA investigational vaccine administration.","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"NI was to be demonstrated if the upper limit of the 2-sided 95% confidence interval (CI) of the group GMT ratio between RSV OA vaccine Group (Overseas) over RSV OA vaccine Group (China) at 1 month post RSVPreF3 OA vaccine administration was ≤ 1.5.","statisticalMethod":"ANCOVA","statisticalComment":"The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.","paramType":"Group GMT Ratio","paramValue":"1.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.95","ciUpperLimit":"1.10","estimateComment":"Comparison is done using the group ratio of adjusted GMT (RSV-OA (Overseas)/RSV-OA (China)) (ANCOVA model applied to the log10- transformed titers)."}]},{"type":"PRIMARY","title":"Percentage of Participants With Seroresponse for RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination","populationDescription":"Analysis was performed on the PPS. As pre-specified in the Protocol, the analysis was performed only on the RSV OA vaccine Group (China) and RSV OA vaccine Group (Overseas). Participants with data available for seroresponse for RSV-B at the specified timepoint were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 31 compared to baseline (Day 1)","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"757"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","lowerLimit":"66.8","upperLimit":"72.2"},{"groupId":"OG001","value":"70.3","lowerLimit":"66.9","upperLimit":"73.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To demonstrate the NI of humoral immune response in Chinese OA enrolled in the RSV OA group (China) compared to OA enrolled in the RSV OA group (Overseas), for the RSV-B strain after the RSVPreF3 OA investigational vaccine administration","nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"NI was to be demonstrated if the upper limit of the 2-sided 95% CI of the group SRR difference between RSV OA vaccine Group (Overseas) over RSV OA vaccine Group (China) at 1 month post RSVPreF3 OA vaccine administration was ≤10%.","paramType":"Group SRR difference","paramValue":"0.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.48","ciUpperLimit":"4.89","estimateComment":"Comparison is done using the difference of SRR (RSV-OA (Overseas) -RSV-OA (China))"}]},{"type":"SECONDARY","title":"RSV-A Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination","description":"Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.","populationDescription":"Analysis was performed on the PPS. As pre-specified in the Protocol, the analysis was performed only on the RSV OA vaccine Group (China) and RSV OA vaccine Group (Overseas). Participants with unadjusted RSV-A GMT data available at the specified timepoints (Day 1, Day 31 and Day 181) were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1191"},{"groupId":"OG001","value":"816"}]}],"classes":[{"title":"Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1191"},{"groupId":"OG001","value":"816"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"703.3","lowerLimit":"674.0","upperLimit":"733.9"},{"groupId":"OG001","value":"825.8","lowerLimit":"776.6","upperLimit":"878.1"}]}]},{"title":"Day 31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"757"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5523.2","lowerLimit":"5254.7","upperLimit":"5805.5"},{"groupId":"OG001","value":"6604.5","lowerLimit":"6194.4","upperLimit":"7041.7"}]}]},{"title":"Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1157"},{"groupId":"OG001","value":"786"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2283.4","lowerLimit":"2173.7","upperLimit":"2398.6"},{"groupId":"OG001","value":"2395.6","lowerLimit":"2253.9","upperLimit":"2546.3"}]}]}]},{"type":"SECONDARY","title":"RSV-B Neutralizing Titers Expressed as Unadjusted GMTs at Baseline, 1 Month and 6 Months Post RSVPreF3 OA Vaccination","description":"Neutralizing titers were measured with neutralization assay and the results were expressed as GMT. Unadjusted GMT is a descriptive statistic calculated directly from the observed titer values at pre-vaccination and at 1-month post-vaccination timepoints for all participants in the analysis set, without any statistical modelling or adjustment for covariates.","populationDescription":"Analysis was performed on the PPS. As pre-specified in the Protocol, the analysis was performed only on the RSV OA vaccine Group (China) and RSV OA vaccine Group (Overseas). Participants with unadjusted RSV-B GMT data available at the specified timepoints (Day 1, Day 31 and Day 181) were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At Day 1 (baseline), Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination)","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1191"},{"groupId":"OG001","value":"816"}]}],"classes":[{"title":"Day 1 (Baseline)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1191"},{"groupId":"OG001","value":"816"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1264.9","lowerLimit":"1209.8","upperLimit":"1322.6"},{"groupId":"OG001","value":"1274.2","lowerLimit":"1194.6","upperLimit":"1359.0"}]}]},{"title":"Day 31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"757"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8073.2","lowerLimit":"7680.5","upperLimit":"8485.9"},{"groupId":"OG001","value":"8286.2","lowerLimit":"7766.3","upperLimit":"8840.9"}]}]},{"title":"Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1158"},{"groupId":"OG001","value":"786"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3931.5","lowerLimit":"3742.4","upperLimit":"4130.1"},{"groupId":"OG001","value":"3785.0","lowerLimit":"3557.0","upperLimit":"4027.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month and 6 Months Post RSVPreF3 OA Vaccination","populationDescription":"Analysis was performed on the PPS. As pre-specified in the Protocol, the analysis was performed only on the RSV OA vaccine Group (China) and RSV OA vaccine Group (Overseas). Participants with data available for seroresponse for RSV-A and RSV-B at the specified timepoints were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 31 (1 month post RSVPreF3 OA vaccination) and Day 181 (6 months post RSVPreF3 OA vaccination) compared to baseline (Day 1)","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"786"}]}],"classes":[{"title":"RSV-A, Day 31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"757"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","lowerLimit":"74.8","upperLimit":"79.6"},{"groupId":"OG001","value":"76.9","lowerLimit":"73.7","upperLimit":"79.8"}]}]},{"title":"RSV-A, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1157"},{"groupId":"OG001","value":"786"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","lowerLimit":"33.9","upperLimit":"39.6"},{"groupId":"OG001","value":"34.0","lowerLimit":"30.7","upperLimit":"37.4"}]}]},{"title":"RSV-B, Day 31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"757"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","lowerLimit":"66.8","upperLimit":"72.2"},{"groupId":"OG001","value":"70.3","lowerLimit":"66.9","upperLimit":"73.5"}]}]},{"title":"RSV-B, Day 181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1158"},{"groupId":"OG001","value":"786"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","lowerLimit":"33.9","upperLimit":"39.6"},{"groupId":"OG001","value":"33.5","lowerLimit":"30.2","upperLimit":"36.9"}]}]}]},{"type":"SECONDARY","title":"RSV-A and RSV-B Neutralizing Titers Expressed as Adjusted GMTs at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group","description":"This outcome measure compares the adjusted GMTs for RSV-A and RSV-B for the RSV OA vaccine Group (China) to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \\[RSV OA Overseas (RSV OA=ADJ-006 study) group\\]. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model includes treatment group as fixed effect, and the pre-dose log10-transformed titers as a covariate.","populationDescription":"Analysis was performed on the PPS. Only participants from RSV OA vaccine Group (China) and the immunogenicity subset of the global RSV OA=ADJ-006 study \\[RSV OA Overseas (RSV OA=ADJ-006 study)\\] with data available for adjusted RSV-A and RSV-B GMTs at the specified timepoint (Day 31) were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"At Day 31","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"RSV OA Overseas (RSV OA=ADJ-006 Study)","description":"Historical cohort of overseas OA participants who received a single dose of RSVPreF3 OA investigational vaccine at Day 1 of the global efficacy study RSV OA=ADJ-006 (NCT04886596)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"832"}]}],"classes":[{"title":"RSV-A","categories":[{"measurements":[{"groupId":"OG000","value":"5790.3","lowerLimit":"5505.8","upperLimit":"6089.4"},{"groupId":"OG001","value":"8670.5","lowerLimit":"8165.7","upperLimit":"9206.6"}]}]},{"title":"RSV-B","categories":[{"measurements":[{"groupId":"OG000","value":"7975.1","lowerLimit":"7611.5","upperLimit":"8356.0"},{"groupId":"OG001","value":"10281.3","lowerLimit":"9726.6","upperLimit":"10867.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To evaluate the humoral immune response of RSV- A titers in Chinese OA enrolled in the RSV OA group (China) compared to OA enrolled in the RSV OA group (Overseas) historical data generated in the immunogenicity subset of the global efficacy study RSV OA=ADJ-006.","nonInferiorityType":"OTHER","nonInferiorityComment":"The statistical analyses performed for the secondary study objectives were descriptive and hence no success criteria were defined for the statistical analyses.","statisticalMethod":"ANCOVA","statisticalComment":"The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.","paramType":"Group GMT Ratio","paramValue":"1.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.38","ciUpperLimit":"1.62","estimateComment":"Comparison is done using the group ratio of adjusted GMT (RSV OA Overseas (RSV OA=ADJ-006 study)/RSV-OA (China)) (ANCOVA model applied to the log10- transformed titers)."},{"groupIds":["OG000","OG001"],"groupDescription":"To evaluate the humoral immune response of RSV- B titers in Chinese OA enrolled in the RSV OA group (China) compared to OA enrolled in the RSV OA group (Overseas) historical data generated in the immunogenicity subset of the global efficacy study RSV OA=ADJ-006.","nonInferiorityType":"OTHER","nonInferiorityComment":"The statistical analyses performed for the secondary study objectives were descriptive and hence no success criteria were defined for the statistical analyses.","statisticalMethod":"ANCOVA","statisticalComment":"The ANCOVA model included the group as fixed effects and the pre-dose log-10 titer as covariate.","paramType":"Group GMT Ratio","paramValue":"1.29","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.20","ciUpperLimit":"1.39","estimateComment":"Comparison is done using the group ratio of adjusted GMT (RSV OA Overseas (RSV OA=ADJ-006 study)/RSV-OA (China)) (ANCOVA model applied to the log10- transformed titers)."}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroresponse for RSV-A and RSV-B Neutralizing Titers at 1 Month Post RSVPreF3 OA Vaccination Between RSV OA Overseas (RSV OA=ADJ-006 Study) vs RSV OA Vaccine Group (China) Group","description":"This outcome measure compares the seroresponse for RSV-A and RSV-B neutralizing titers in the RSV OA vaccine Group (China) group to the selected immunogenicity subset of the global efficacy study RSV OA=ADJ-006 \\[RSV OA Overseas (RSV OA=ADJ-006 study) group\\].","populationDescription":"Analysis was performed on the PPS. Only participants from RSV OA vaccine Group (China) and the immunogenicity subset of the global RSV OA=ADJ-006 study \\[RSV OA Overseas (RSV OA=ADJ-006 study)\\] with data available for seroresponse for RSV-A and RSV-B at the specified timepoints (Day 1 and Day 31) were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"At Day 31 compared to baseline (Day 1)","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"RSV OA Overseas (RSV OA=ADJ-006 Study)","description":"Historical cohort of overseas OA participants who received a single dose of RSVPreF3 OA investigational vaccine at Day 1 of the global efficacy study RSV OA=ADJ-006 (NCT04886596)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1175"},{"groupId":"OG001","value":"832"}]}],"classes":[{"title":"RSV-A","categories":[{"measurements":[{"groupId":"OG000","value":"77.3","lowerLimit":"74.8","upperLimit":"79.6"},{"groupId":"OG001","value":"81.6","lowerLimit":"78.8","upperLimit":"84.2"}]}]},{"title":"RSV-B","categories":[{"measurements":[{"groupId":"OG000","value":"69.5","lowerLimit":"66.8","upperLimit":"72.2"},{"groupId":"OG001","value":"78.6","lowerLimit":"75.7","upperLimit":"81.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To evaluate the humoral immune response of RSV- A titers in Chinese OA enrolled in the RSV OA group (China) compared to OA enrolled in the RSV OA group (Overseas) historical data generated in the immunogenicity subset of the global efficacy study RSV OA=ADJ-006.","nonInferiorityType":"OTHER","nonInferiorityComment":"The statistical analyses performed for the secondary study objectives were descriptive and hence no success criteria were defined for the statistical analyses.","paramType":"Group SRR difference","paramValue":"4.33","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"7.86","estimateComment":"Comparison is done using the difference of SRR (RSV OA Overseas (RSV OA=ADJ-006 study) - RSV-OA (China))."},{"groupIds":["OG000","OG001"],"groupDescription":"To evaluate the humoral immune response of RSV- B titers in Chinese OA enrolled in the RSV OA group (China) compared to OA enrolled in the RSV OA group (Overseas) historical data generated in the immunogenicity subset of the global efficacy study RSV OA=ADJ-006.","nonInferiorityType":"OTHER","nonInferiorityComment":"The statistical analyses performed for the secondary study objectives were descriptive and hence no success criteria were defined for the statistical analyses.","paramType":"Group SRR difference","paramValue":"9.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.20","ciUpperLimit":"12.87","estimateComment":"Comparison is done using the difference of SRR (RSV OA Overseas (RSV OA=ADJ-006 study) - RSV-OA (China))."}]},{"type":"SECONDARY","title":"Number of Participants With Any and Real Time Polymerase Chain Reaction (RT-PCR) Confirmed RSV-A/B Associated Acute Respiratory Illness (ARI) and Lower Respiratory Tract Disease (LRTD) Cases","description":"ARI and LRTD were reported based on the case definition. Case definition for ARI: presence of at least 2 respiratory symptoms/signs for at least 24 hours or at least 1 respiratory symptom/sign and 1 systemic symptom/sign for at least 24 hours. Case definition for LRTD: presence of at least 2 lower respiratory symptoms/signs for at least 24 hours including at least 1 lower respiratory sign or at least 3 lower respiratory symptoms for at least 24 hours.","populationDescription":"Analysis was performed on the exposed set (ES) which included all participants who received the study intervention. As pre-specified in Protocol, data for this outcome measure were collected only for the Chinese participants (RSV OA vaccine Group \\[China\\] and Placebo Group \\[China\\]), from which only those participants with data available at the specified time period were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1199"},{"groupId":"OG001","value":"601"}]}],"classes":[{"title":"Any ARI","categories":[{"measurements":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"65"}]}]},{"title":"RSV-confirmed ARI","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Any LRTD","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"13"}]}]},{"title":"RSV-confirmed LRTD","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Duration of Episodes for RSV-confirmed ARI and LRTD Cases","populationDescription":"Analysis was performed on the ES. As pre-specified in Protocol, data for this outcome measure were collected only for the Chinese participants (RSV OA vaccine Group \\[China\\] and Placebo Group \\[China\\]), from which only those participants with RSV-confirmed ARI/LRTD cases at the specified time period (Placebo Group \\[China\\]) were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"Days","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])","typeUnitsAnalyzed":"Episodes","denomUnitsSelected":"Episodes","groups":[{"id":"OG000","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"3"}]}],"classes":[{"title":"Duration of RSV-confirmed ARI","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","lowerLimit":"17.0","upperLimit":"20.0"}]}]},{"title":"Duration of RSV-confirmed LRTD","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","lowerLimit":"17.0","upperLimit":"17.0"}]}]}]},{"type":"SECONDARY","title":"Number of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed ARI Cases","populationDescription":"Analysis was performed on the ES. As pre-specified in Protocol, data for this outcome measure were collected only for the Chinese participants (RSV OA vaccine Group \\[China\\] and Placebo Group \\[China\\]), from which only those participants with RSV-confirmed ARI cases at the specified time period (Placebo Group \\[China\\]) were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_UNITS","unitOfMeasure":"Episodes","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])","typeUnitsAnalyzed":"Episodes","denomUnitsSelected":"Episodes","groups":[{"id":"OG000","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"classes":[{"title":"Nasal Congestion","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Rhinorrhea","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Sore Throat","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Cough (new or increased)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Sputum (new or increased)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Shortness of breath or dyspnea (new or increased)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Wheezing (new or increased)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Crackles","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Rhonchi","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Respiratory rate >=20 breaths/min","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Low or decreased oxygen saturation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Fever","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Feverishness","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Fatigue","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Body aches","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Headache","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Decreased appetite","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Need for oxygen supplementation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Need for positive airway pressure therapy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Need of other types of mechanical ventilation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Other symptoms or signs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Episodes of Each of the Symptoms/Signs Associated to RSV-confirmed LRTD Cases","populationDescription":"Analysis was performed on the ES. As pre-specified in Protocol, data for this outcome measure were collected only for the Chinese participants (RSV OA vaccine Group \\[China\\] and Placebo Group \\[China\\]), from which only those participants with RSV-confirmed LRTD cases at the specified time period (Placebo Group \\[China\\]) were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_UNITS","unitOfMeasure":"Episodes","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])","typeUnitsAnalyzed":"Episodes","denomUnitsSelected":"Episodes","groups":[{"id":"OG000","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]},{"units":"Episodes","counts":[{"groupId":"OG000","value":"1"}]}],"classes":[{"title":"Nasal Congestion","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Rhinorrhea","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Sore Throat","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Cough (new or increased)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Sputum (new or increased)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Shortness of breath or dyspnea (new or increased)","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Wheezing (new or increased)","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Crackles","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Rhonchi","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Respiratory rate >=20 breaths/min","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Low or decreased oxygen saturation","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Fever","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Feverishness","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Body aches","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Decreased appetite","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Need for oxygen supplementation","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Need for positive airway pressure therapy","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Need of other types of mechanical ventilation","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Other symptoms or signs","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With RSV-confirmed ARI and LRTD Episodes by Severity","description":"The severity was measured as mild, moderate or severe. Mild= An ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate=An ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe=An ARI/LRTD episode which prevents normal, everyday activities. Such an event would, for example, prevent attendance at work and would necessitate the administration of corrective therapy.","populationDescription":"Analysis was performed on the ES. As pre-specified in Protocol, data for this outcome measure were collected only for the Chinese participants (RSV OA vaccine Group \\[China\\] and Placebo Group \\[China\\]), from which only those participants with RSV-confirmed ARI/LRTD cases at the specified time period (Placebo Group \\[China\\]) were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])","groups":[{"id":"OG000","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"classes":[{"title":"RSV-confirmed ARI","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"1"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"1"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"RSV-confirmed LRTD","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"1"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"0"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With RSV-confirmed ARI and LRTD Episodes by Frailty Status","description":"The frailty status was evaluated as frail, pre-frail, and fit. Frail=Participants with a walking speed \\<0.4 meters per second (m/s) or who were not able to perform the test. Pre-frail=Participants with a walking speed between 0.4-0.99 m/s. Fit=Participants with a walking speed ≥1 m/s.","populationDescription":"Analysis was performed on the ES. As pre-specified in Protocol, data for this outcome measure were collected only for the Chinese participants (RSV OA vaccine Group \\[China\\] and Placebo Group \\[China\\]), from which only those participants with RSV-confirmed ARI/LRTD cases at the specified time period (Placebo Group \\[China\\]) were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 15 and up to study end (6 months post dose [dose administered at Day 1])","groups":[{"id":"OG000","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"}]}],"classes":[{"title":"RSV-confirmed ARI","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"}]}],"categories":[{"title":"Frail","measurements":[{"groupId":"OG000","value":"0"}]},{"title":"Pre-Frail","measurements":[{"groupId":"OG000","value":"0"}]},{"title":"Fit","measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"RSV-confirmed LRTD","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"}]}],"categories":[{"title":"Frail","measurements":[{"groupId":"OG000","value":"0"}]},{"title":"Pre-Frail","measurements":[{"groupId":"OG000","value":"0"}]},{"title":"Fit","measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Any Solicited Administration Site Adverse Events","description":"Assessed solicited administration site adverse events were pain, redness (erythema) and swelling at administration site. Any = occurrence of the symptom regardless of intensity grade.","populationDescription":"Analysis was performed on the ES. As pre-specified in Protocol, data for this outcome measure were collected only for the Chinese groups (RSV OA vaccine Group \\[China\\] and Placebo Group \\[China\\]), from which only those participants with data available for solicited administration site adverse events at the specified time period were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (baseline) to Day 7","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1193"},{"groupId":"OG001","value":"599"}]}],"classes":[{"title":"Pain","categories":[{"measurements":[{"groupId":"OG000","value":"497"},{"groupId":"OG001","value":"25"}]}]},{"title":"Erythema","categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"3"}]}]},{"title":"Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Any Solicited Systemic Adverse Events","description":"Assessed solicited systemic adverse events were fever (pyrexia), headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever was defined as body temperature greater or equal to (≥) 38 degrees Celsius (ºC). Any = occurrence of the symptom regardless of intensity grade.","populationDescription":"Analysis was performed on the ES. As pre-specified in Protocol, data for this outcome measure were collected only for the Chinese groups (RSV OA vaccine Group \\[China\\] and Placebo Group \\[China\\]), from which only those participants with data available for solicited systemic adverse events at the specified time period were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (baseline) to Day 7","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1193"},{"groupId":"OG001","value":"600"}]}],"classes":[{"title":"Arthralgia","categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"11"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"19"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"14"}]}]},{"title":"Myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"12"}]}]},{"title":"Fever","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Any Unsolicited Adverse Events (AEs)","description":"An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the symptom regardless of intensity grade.","populationDescription":"Analysis was performed on the ES. As pre-specified in Protocol, data for this outcome measure was presented only for the Chinese participants (RSV OA vaccine Group \\[China\\] and Placebo Group \\[China\\]), from which only those participants with data available for the specified analysis at the specified time period were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (baseline) to Day 30","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG001","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1199"},{"groupId":"OG001","value":"601"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"70"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs","description":"An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of the intensity grade or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.","populationDescription":"Analysis was performed on the ES. Only those participants with data available for SAEs at the specified time period were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."},{"id":"OG001","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG002","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"820"},{"groupId":"OG001","value":"1199"},{"groupId":"OG002","value":"601"}]}],"classes":[{"title":"Any SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"39"}]}]},{"title":"Related SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}]},{"title":"Fatal SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Any Potential Immune-mediated Disease (pIMDs) and Related pIMDs","description":"pIMDs are a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of the intensity grade or relation to study vaccination. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination.","populationDescription":"Analysis was performed on the ES. Only those participants with data available for pIMDs at the specified time period were reported in this outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 to end of study (Month 6 for overseas participants; Month 6 or last ARI visit/contact, whichever is later, for study participants in China)","groups":[{"id":"OG000","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6)."},{"id":"OG001","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later)."},{"id":"OG002","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"820"},{"groupId":"OG001","value":"1199"},{"groupId":"OG002","value":"601"}]}],"classes":[{"title":"Any pIMDs","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}]}]},{"title":"Related pIMDs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Solicited AEs: Day 1 (day of vaccination) up to Day 7. Unsolicited AEs: Day 1 up to Day 30. All-cause mortality, any SAEs, related SAEs, fatal SAEs, any pIMDs, related pIMDs: Day 1 up to study end (Month 6 for oversea participants; Month 6 or or last ARI visit/contact, whichever is later, for participants in China)","eventGroups":[{"id":"EG000","title":"RSV OA Vaccine Group (Overseas)","description":"Overseas OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6).","deathsNumAffected":2,"deathsNumAtRisk":820,"seriousNumAffected":28,"seriousNumAtRisk":820,"otherNumAffected":2,"otherNumAtRisk":820},{"id":"EG001","title":"RSV OA Vaccine Group (China)","description":"Chinese OA participants received a single dose of RSVPreF3 OA investigational vaccine at Day 1 and were followed up until end of study (Month 6 or last acute respiratory illness (ARI) visit/contact, whichever was later).","deathsNumAffected":2,"deathsNumAtRisk":1199,"seriousNumAffected":53,"seriousNumAtRisk":1199,"otherNumAffected":640,"otherNumAtRisk":1199},{"id":"EG002","title":"Placebo Group (China)","description":"Chinese OA participants received a single dose of placebo at Day 1 and were followed up until end of study (Month 6 or last ARI visit/contact, whichever was later).","deathsNumAffected":0,"deathsNumAtRisk":601,"seriousNumAffected":39,"seriousNumAtRisk":601,"otherNumAffected":108,"otherNumAtRisk":601}],"seriousEvents":[{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Cor pulmonale","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Sinus arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Hypertensive heart disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1199},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":601}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":601}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Bronchiectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pulmonary mass","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Bronchitis chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pulmonary bullae rupture","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":820},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1199},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":601}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Chronic sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":601}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Large intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Obstructive pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Intestinal mass","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Salivary gland mass","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":601}]},{"term":"Lacunar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Vertebrobasilar insufficiency","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Cerebral artery occlusion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Persistent postural-perceptual dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Facial spasm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Meniscus injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Multiple fractures","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":601}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Foot deformity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Gouty arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Synovitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":601}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pelvic organ prolapse","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Uterine disorder","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Cystocele","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Gastric cancer stage I","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Colorectal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Type 3 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Focal segmental glomerulosclerosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Cholecystitis chronic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Acute cholecystitis necrotic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Immune thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Adenomatous polyposis coli","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Infective exacerbation of bronchiectasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]}],"otherEvents":[{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":497,"numAffected":497,"numAtRisk":1199},{"groupId":"EG002","numEvents":25,"numAffected":25,"numAtRisk":601}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":166,"numAffected":164,"numAtRisk":1199},{"groupId":"EG002","numEvents":19,"numAffected":19,"numAtRisk":601}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":88,"numAffected":88,"numAtRisk":1199},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":601}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":82,"numAffected":82,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":49,"numAffected":49,"numAtRisk":1199},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":601}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Administration site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Swelling face","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Vaccination site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Vaccination site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":127,"numAffected":125,"numAtRisk":1199},{"groupId":"EG002","numEvents":12,"numAffected":12,"numAtRisk":601}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":71,"numAffected":69,"numAtRisk":1199},{"groupId":"EG002","numEvents":11,"numAffected":11,"numAtRisk":601}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":97,"numAffected":95,"numAtRisk":1199},{"groupId":"EG002","numEvents":15,"numAffected":15,"numAtRisk":601}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Cerebrovascular insufficiency","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Facial paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Post herpetic neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":19,"numAffected":19,"numAtRisk":1199},{"groupId":"EG002","numEvents":11,"numAffected":11,"numAtRisk":601}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":601}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":601}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":601}]},{"term":"Periodontitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1199},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":601}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pulpitis dental","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Urethritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Conjunctivitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Helicobacter infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Myringitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Subungual abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Tinea pedis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Upper respiratory tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":601}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":1199},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":601}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Bronchitis chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pulmonary mass","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1199},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":601}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Angular cheilitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Dysbiosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Tooth disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Peptic ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":601}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Hyperkeratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Supraventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Atrioventricular block first degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":601}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":820},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Renal cyst","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Micturition urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Ureteric stenosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Hepatic steatosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Hepatic cyst","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":601}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Thyroid mass","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Uterine mass","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Scratch","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Tumour marker increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1199},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":601}]},{"term":"Influenza A virus test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Ear inflammation","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Gingivitis1","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v28.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":820},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1199},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":601}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","email":"GSKClinicalSupportHD@gsk.com","phone":"866-435-7343"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2024-02-15","uploadDate":"2026-04-24T01:54","filename":"Prot_000.pdf","size":1385473},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2025-08-06","uploadDate":"2026-04-24T01:54","filename":"SAP_001.pdf","size":976574}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D018357","term":"Respiratory Syncytial Virus Infections"}],"ancestors":[{"id":"D018186","term":"Pneumovirus Infections"},{"id":"D018184","term":"Paramyxoviridae Infections"},{"id":"D018701","term":"Mononegavirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077330","term":"Saline Solution"}],"ancestors":[{"id":"D000077324","term":"Crystalloid Solutions"},{"id":"D007552","term":"Isotonic Solutions"},{"id":"D012996","term":"Solutions"},{"id":"D004364","term":"Pharmaceutical Preparations"}]}},"hasResults":true}